BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 19301897)

  • 1. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
    Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
    J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
    Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
    J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation.
    Parmenon C; Guillard J; Caignard DH; Hennuyer N; Staels B; Audinot-Bouchez V; Boutin JA; Dacquet C; Ktorza A; Viaud-Massuard MC
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1617-22. PubMed ID: 18255290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.
    Rau O; Syha Y; Zettl H; Kock M; Bock A; Schubert-Zsilavecz M
    Arch Pharm (Weinheim); 2008 Mar; 341(3):191-5. PubMed ID: 18275039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.
    Shi GQ; Dropinski JF; McKeever BM; Xu S; Becker JW; Berger JP; MacNaul KL; Elbrecht A; Zhou G; Doebber TW; Wang P; Chao YS; Forrest M; Heck JV; Moller DE; Jones AB
    J Med Chem; 2005 Jun; 48(13):4457-68. PubMed ID: 15974597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.
    Parmenon C; Guillard J; Caignard DH; Hennuyer N; Staels B; Audinot-Bouchez V; Boutin JA; Dacquet C; Ktorza A; Viaud-Massuard MC
    Bioorg Med Chem Lett; 2009 May; 19(10):2683-7. PubMed ID: 19376700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
    Yu R; Zhou YL; Huan Y; Liu Q; Shen ZF; Liu ZZ
    Yao Xue Xue Bao; 2011 Mar; 46(3):311-6. PubMed ID: 21626786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
    Humphries PS; Bailey S; Almaden JV; Barnum SJ; Carlson TJ; Christie LC; Do QQ; Fraser JD; Hess M; Kellum J; Kim YH; McClellan GA; Ogilvie KM; Simmons BH; Skalitzky D; Sun S; Wilhite D; Zehnder LR
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6120-3. PubMed ID: 16973358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists.
    Popescu L; Rau O; Böttcher J; Syha Y; Schubert-Zsilavecz M
    Arch Pharm (Weinheim); 2007 Jul; 340(7):367-71. PubMed ID: 17610302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists.
    Peng YH; Coumar MS; Leou JS; Wu JS; Shiao HY; Lin CH; Lin WH; Lien TW; Chen X; Hsu JT; Chao YS; Huang CF; Lyu PC; Hsieh HP; Wu SY
    ChemMedChem; 2010 Oct; 5(10):1707-16. PubMed ID: 20734309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
    J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
    Matin A; Gavande N; Kim MS; Yang NX; Salam NK; Hanrahan JR; Roubin RH; Hibbs DE
    J Med Chem; 2009 Nov; 52(21):6835-50. PubMed ID: 19807106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists.
    Kuhn B; Hilpert H; Benz J; Binggeli A; Grether U; Humm R; Märki HP; Meyer M; Mohr P
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4016-20. PubMed ID: 16737814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.
    Zaware P; Shah SR; Pingali H; Makadia P; Thube B; Pola S; Patel D; Priyadarshini P; Suthar D; Shah M; Jamili J; Sairam KV; Giri S; Patel L; Patel H; Sudani H; Patel H; Jain M; Patel P; Bahekar R
    Bioorg Med Chem Lett; 2011 Jan; 21(2):628-32. PubMed ID: 21195611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
    Suh YG; Kim NJ; Koo BW; Lee KO; Moon SH; Shin DH; Jung JW; Paek SM; Chang DJ; Li F; Kang HJ; Le TV; Chae YN; Shin CY; Kim MK; Lim JI; Ryu JS; Park HJ
    J Med Chem; 2008 Oct; 51(20):6318-33. PubMed ID: 18826205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
    Itoh T; Murota I; Yoshikai K; Yamada S; Yamamoto K
    Bioorg Med Chem; 2006 Jan; 14(1):98-108. PubMed ID: 16198578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
    Devasthale PV; Chen S; Jeon Y; Qu F; Ryono DE; Wang W; Zhang H; Cheng L; Farrelly D; Golla R; Grover G; Ma Z; Moore L; Seethala R; Sun W; Doweyko AM; Chandrasena G; Sleph P; Hariharan N; Cheng PT
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2312-6. PubMed ID: 17292606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists.
    Oon Han H; Kim SH; Kim KH; Hur GC; Joo Yim H; Chung HK; Ho Woo S; Dong Koo K; Lee CS; Sung Koh J; Kim GT
    Bioorg Med Chem Lett; 2007 Feb; 17(4):937-41. PubMed ID: 17157019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
    Humphries PS; Almaden JV; Barnum SJ; Carlson TJ; Do QQ; Fraser JD; Hess M; Kim YH; Ogilvie KM; Sun S
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6116-9. PubMed ID: 16979341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.